**Lenacapavir Pre-exposure Prophylaxis (PrEP)** is a study to understand how people use a medicine called Lenacapavir, or LEN, to prevent HIV, a virus that affects the immune system. PrEP stands for pre-exposure prophylaxis, which means taking medicine to prevent getting HIV before being exposed to it. This study looks at how people begin, continue, or stop using Lenacapavir for HIV prevention in different healthcare locations in the United States.

Participants must understand and agree to the study rules. They need to be interested in using PrEP for HIV prevention and be eligible, meaning they must test negative for HIV. The study involves learning about different PrEP options and deciding whether Lenacapavir is the right choice for them.

• The study lasts 52 weeks, or about one year.
• Participants must visit study sites and follow guidelines.
• Participants will learn about different PrEP options before choosing.

People who don't meet the criteria or have other health issues may not be eligible to participate. It's crucial for participants to be committed to the study requirements to help researchers gather valuable information about Lenacapavir's real-world use.